Kvelux

Quetiapine, the active ingredient in Kvelux, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia, bipolar disorder (both manic and depressive phases), and as an adjunct in major depressive disorder in adult patients.

GNH USA supplies Kvelux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Quetiapine is used in psychiatric disorders that involve dysregulation of dopamine and serotonin pathways. - Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar disorder (manic and depressive episodes): stabilizes mood and decreases the frequency and severity of manic or depressive episodes. - Adjunct treatment of major depressive disorder: enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, which are categorized by frequency. Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis - Severe orthostatic hypotension

When prescribing quetiapine, clinicians should consider several precautionary measures to ensure patient safety. - Assess cardiovascular status: monitor blood pressure and heart rate, especially during dose initiation. - Evaluate metabolic risk: screen for diabetes, lipid abnormalities, and weight changes. - Review psychiatric history: avoid abrupt discontinuation to prevent rebound psychosis or withdrawal. - Consider hepatic or renal impairment: adjust dosing or monitor plasma levels as needed. - Use caution in elderly patients: increased sensitivity to sedation and falls. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and light.

Quetiapine can interact with other medicines, altering its effectiveness or safety profile. Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma concentrations, raising risk of toxicity. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Antihypertensive agents: enhanced hypotensive effect leading to dizziness or fainting. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce quetiapine levels, decreasing efficacy. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Lithium: combined use may increase risk of neurotoxicity.